BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Lin CY, Bai DJ, Yuan HY, Wang K, Yang GL, Hu MB, Wu ZQ, Li Y. Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: Results of a randomized controlled clinical trial. World J Gastroenterol 2004; 10(1): 136-142 [PMID: 14695785 DOI: 10.3748/wjg.v10.i1.136]
URL: https://www.wjgnet.com/1007-9327/full/v10/i1/136.htm
Number Citing Articles
1
Martina Kubecova, Katarina Kolostova, Daniela Pinterova, Grzegorz Kacprzak, Vladimir Bobek. Cimetidine: An anticancer drug?European Journal of Pharmaceutical Sciences 2011; 42(5): 439 doi: 10.1016/j.ejps.2011.02.004
2
Robert O. Dillman. Cancer ImmunotherapyCancer Biotherapy and Radiopharmaceuticals 2011; 26(1): 1 doi: 10.1089/cbr.2010.0902
3
Ahmad H. Ali, Laurie Hale, Bindu Yalamanchili, Mashrafi Ahmed, Marwa Ahmed, Rixin Zhou, Stephen E. Wright. The Effect of Perioperative Cimetidine Administration on Time to Colorectal Cancer RecurrenceAmerican Journal of Therapeutics 2018; 25(4): e405 doi: 10.1097/MJT.0000000000000547
4
Sanjeev Deva, Michael Jameson. Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancerCochrane Database of Systematic Reviews 2012;  doi: 10.1002/14651858.CD007814.pub2
5
Bin Pan, Tao Cheng, Ke-Jun Nan, Gen-Quan Qiu, Xi-Cai Sun. Effect of Fuzheng Yiliu decoction combined with chemotherapy on patients with intermediate and late stage gastrointestinal cancerWorld Journal of Gastroenterology 2005; 11(3): 439-442 doi: 10.3748/wjg.v11.i3.439
6
Phuong Linh Nguyen, Jungsook Cho. Pathophysiological Roles of Histamine Receptors in Cancer Progression: Implications and Perspectives as Potential Molecular TargetsBiomolecules 2021; 11(8): 1232 doi: 10.3390/biom11081232
7
Sanjeev Deva, Michael Jameson, Sanjeev Deva. Cochrane Database of Systematic Reviews2009;  doi: 10.1002/14651858.CD007814
8
Anette T. Hansen Selnø, Vadim V. Sumbayev, Ulrike Raap, Bernhard F. Gibbs. Immunopharmacology and Inflammation2018; : 85 doi: 10.1007/978-3-319-77658-3_4
9
J.H. Park, D.C. McMillan, P.G. Horgan, C.S. Roxburgh. The impact of anti-inflammatory agents on the outcome of patients with colorectal cancerCancer Treatment Reviews 2014; 40(1): 68 doi: 10.1016/j.ctrv.2013.05.006
10
Gerben J. van der Bij, Steven J. Oosterling, Robert H. J. Beelen, Sybren Meijer, John C. Coffey, Marjolein van Egmond. The Perioperative Period is an Underutilized Window of Therapeutic Opportunity in Patients With Colorectal CancerAnnals of Surgery 2009; 249(5): 727 doi: 10.1097/SLA.0b013e3181a3ddbd
11
Hideyuki Ubukata, Hiroyuki Nagata, Takanobu Tabuchi, Satoru Konishi, Teruhiko Kasuga, Takafumi Tabuchi. Why is the coexistence of gastric cancer and duodenal ulcer rare? Examination of factors related to both gastric cancer and duodenal ulcerGastric Cancer 2011; 14(1): 4 doi: 10.1007/s10120-011-0005-9
12
Benjamin Purow. Repurposing existing agents as adjunct therapies for glioblastomaNeuro-Oncology Practice 2016; 3(3): 154 doi: 10.1093/nop/npv041
13
Tomas Koltai, Stephan J. Reshkin, Salvador Harguindey. An Innovative Approach to Understanding and Treating Cancer: Targeting pH2020; : 361 doi: 10.1016/B978-0-12-819059-3.00016-2